Indira IVF Commences Global Aspirations, Enters International Fertility Market
Indira IVF, India’s largest network of infertility treatment hospitals, has announced its international foray with the inauguration of its hospital...
Month: January 2024
Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio
On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection, securing exclusive commercialization licensing...
Mindful Therapy Group Expands Leadership Team to Drive Innovation & Support Growth
Mindful Therapy Group (Mindful), a collaborative network of over 1,000 licensed, independent mental health clinicians, today announced the addition of two...
Clinical trial on Ambio Life Sciences’ ibogaine treatment for Navy SEALs with traumatic brain injury published in Nature Medicine
Today, Nature Medicine published the results of a clinical trial, in which 30 former Navy SEALs were administered ibogaine at Ambio Life Sciences in Mexico to...
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of...
SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease
SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of innovative therapies for kidney diseases, today announces...
Target RWE Launches Novel Precision Medicine Platform to Undertake Growing Unmet Medical Needs in Liver Disease, Gastroenterology, and Immune-mediated Inflammatory Conditions
Real-world evidence (RWE) leader, Target RWE, today announced its innovative Precision Medicine Platform, a robust biorepository of 150,000+ samples collected along...
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
Alkermes plc (Nasdaq: ALKS) today announced topline results from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability...
Equality Health Brings Proven “Medicaid-First” Value-Based Care Model to Virginia
Equality Health, a national leader in value-based care, today announced its latest expansion into the Commonwealth of Virginia, offering its proven...
